open access

Ahead of print
Research paper (original)
Published online: 2021-11-05
Get Citation

Prognostic significance of sex in patients with primary tracheal tumors – a retrospective, single-center study

Aleksandra Piórek1, Adam Płużański1, Dariusz Mirosław Kowalski1, Maciej Krzakowski1
DOI: 10.5603/NJO.a2021.0069
Affiliations
  1. Lung Cancer and Chest Tumours Department, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

open access

Ahead of print
Original article
Published online: 2021-11-05

Abstract

Introduction. We aimed to assess the prognostic significance of sex in patients with primary tracheal tumors based on our own results as well as a literature review.

Material and methods. We carried out a retrospective analysis of 89 patients with primary tracheal tumors treated at the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland, between January 2000 and December 2016. Men and women were compared in terms of overall survival, disease-free survival, and progression-free survival.

Results. In the entire study group, the median overall survival was 61.30 months in women and 8.55 months in men (p < 0.0001). 5-year overall survival rates were 2.1% in men versus 50.6% in women (p < 0.0001). Among those receiving radical treatment, women had improved survival rates compared with men. Sex was an independent prognostic factor in both the total study population and among those undergoing radical treatment.

Conclusions. According to our results, women with primary tracheal tumors have significantly better survival than men. Because female sex is an independent prognostic factor in patients with primary tracheal tumors, the ratio of women to men should be taken into consideration in reports comparing the outcomes of different treatments.

Abstract

Introduction. We aimed to assess the prognostic significance of sex in patients with primary tracheal tumors based on our own results as well as a literature review.

Material and methods. We carried out a retrospective analysis of 89 patients with primary tracheal tumors treated at the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland, between January 2000 and December 2016. Men and women were compared in terms of overall survival, disease-free survival, and progression-free survival.

Results. In the entire study group, the median overall survival was 61.30 months in women and 8.55 months in men (p < 0.0001). 5-year overall survival rates were 2.1% in men versus 50.6% in women (p < 0.0001). Among those receiving radical treatment, women had improved survival rates compared with men. Sex was an independent prognostic factor in both the total study population and among those undergoing radical treatment.

Conclusions. According to our results, women with primary tracheal tumors have significantly better survival than men. Because female sex is an independent prognostic factor in patients with primary tracheal tumors, the ratio of women to men should be taken into consideration in reports comparing the outcomes of different treatments.

Get Citation

Keywords

tracheal tumors; adenoid cystic carcinoma of the trachea; squamous cell carcinoma of the trachea; sex

About this article
Title

Prognostic significance of sex in patients with primary tracheal tumors – a retrospective, single-center study

Journal

Nowotwory. Journal of Oncology

Issue

Ahead of print

Article type

Research paper (original)

Published online

2021-11-05

DOI

10.5603/NJO.a2021.0069

Keywords

tracheal tumors
adenoid cystic carcinoma of the trachea
squamous cell carcinoma of the trachea
sex

Authors

Aleksandra Piórek
Adam Płużański
Dariusz Mirosław Kowalski
Maciej Krzakowski

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl